1350925-21-1

Basic information

• Product Name: 6-chloropyrido[3,2-b]pyrazin-3(4H)-one
• Synonyms: 6-chloropyrido[3,2-b]pyrazin-3(4H)-one;6-chloropyrido[2,3-b]pyrazin-3(4H)-one
• CAS NO: 1350925-21-1
• Molecular Formula: C7H4ClN3O
• Molecular Weight: 181.57916
• Mol File: 1350925-21-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-chloropyrido[3,2-b]pyrazin-3(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloropyrido[3,2-b]pyrazin-3(4H)-one(1350925-21-1)
• EPA Substance Registry System: 6-chloropyrido[3,2-b]pyrazin-3(4H)-one(1350925-21-1)

Safety Data

• Hazardous Substances Data: 1350925-21-1(Hazardous Substances Data)

Usage

General Description

6-chloropyrido[3,2-b]pyrazin-3(4H)-one is a chemical compound with the molecular formula C8H5ClN4O. It is a heterocyclic compound containing a pyridine ring fused to a pyrazine ring, with a chlorine group attached to the pyridine ring. 6-chloropyrido[3,2-b]pyrazin-3(4H)-one is used as a building block in organic synthesis and can be used in the production of pharmaceuticals, agrochemicals, and dyes. It has potential applications in the development of new drugs and therapeutic agents due to its unique chemical structure and reactivity. Additionally, it exhibits interesting biological activities that make it a valuable target for further research and development in the field of medicinal chemistry.

Upstream product

• 27048-04-0 2-amino-6-chloro-3-nitropyridine 
• 1350925-20-0 6-chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one 
• 146015-42-1 6-chloro-2-nitropyridine-3-amine 
• 40851-95-4 6-chloropyridine-2,3-diamine 

Downstream Products

• 1350925-22-2 3,6-dichloropyrido[2,3-b]pyrazine 

Relevant articles and documents

OXAZOLIDINONE ANTIBIOTIC COMPOUNDS AND PROCESS OF PREPARATION

The present disclosure relates to compounds of Formula (I), its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by microbes. The present disclosure also relates to the synthesis and characterization of aforementioned substances.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.